NCT04765709 - Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Non-small Cell Lung Cancer Stage III

Interventions

COMBINATION_PRODUCT

durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)

Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).

COMBINATION_PRODUCT

Durvalumab plus radiotherapy

Concomitant durvalumab and radiotherapy

BIOLOGICAL

durvalumab

Consolidation treatment with durvalumab

Trial Locations (3)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Unknown

Gustave Roussy Institute, Paris

Vall d'Hebron Barcelona Hospital, Barcelona